A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC).
Affiliation
Drug Development, Istituto Europeo di Oncologia, Milan, ItalyIssue Date
2016-10-01
Metadata
Show full item recordCitation
A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC). 2016, 27(suppl 6):312TiP Annals of OncologyJournal
Annals of OncologyDOI
10.1093/annonc/mdw365.91Additional Links
https://academic.oup.com/annonc/article/2799051/AType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw365.91